AUROPHARMA Share Price Target 2040

CAGR-based price projection for Aurobindo Pharma Limited (AUROPHARMA) targeting 2040, derived from official NSE exchange closing prices.

Bear Case (9.7% CAGR)
Rs 6,133
2040 Target
Base Case (24.3% CAGR)
Rs 35,095
2040 Target
Bull Case (70.7% CAGR)
Rs 2,999,298
2040 Target

Current Market Snapshot

CMP: Rs 1,676.80
52W High: Rs 1,734.00
52W Low: Rs 1,339.80
1Y CAGR: 54.4%
3Y CAGR: 24.3%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,840 Rs 2,084 Rs 2,863
2028 Rs 2,018 Rs 2,589 Rs 4,888
2029 Rs 2,214 Rs 3,217 Rs 8,346
2030 Rs 2,429 Rs 3,998 Rs 14,249
2031 Rs 2,664 Rs 4,968 Rs 24,328
2032 Rs 2,923 Rs 6,173 Rs 41,536
2033 Rs 3,207 Rs 7,671 Rs 70,917
2034 Rs 3,518 Rs 9,532 Rs 121,081
2035 Rs 3,859 Rs 11,845 Rs 206,728
2036 Rs 4,234 Rs 14,719 Rs 352,958
2037 Rs 4,645 Rs 18,291 Rs 602,625
2038 Rs 5,096 Rs 22,728 Rs 1,028,896
2039 Rs 5,590 Rs 28,243 Rs 1,756,691
2040 Rs 6,133 Rs 35,095 Rs 2,999,298

Other AUROPHARMA Price Targets

2025 2026 2027 2028 2030 2035 2050

Frequently Asked Questions

What is the AUROPHARMA share price target for 2040?

Based on historical growth analysis, the AUROPHARMA share price target for 2040 ranges from Rs 6,133 (conservative) to Rs 35,095 (base case) to Rs 2,999,298 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of AUROPHARMA?

The current market price of AUROPHARMA (Aurobindo Pharma Limited) is Rs 1,676.80. The 52-week high is Rs 1,734.00 and 52-week low is Rs 1,339.80.

Is AUROPHARMA a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for AUROPHARMA price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 9.7% CAGR), Base (24.3% CAGR), and Bull (optimistic at 70.7% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.